Despite significant therapeutic advance, there are 26 million heart failure patients world wide. Heart failure (HF) represents a primary cause of morbidity and mortality in older people. HF is still characterized by important unmet needs, thus remaining a challenging field of clinical research. Recently, a new promising drug for HF has been proposed LCZ696, which is a combination of sacubitril and valsartan.
This article will present a general overview of sacubitril/valsartan combination. The sacubitril/valsartan is a combination of neprilysin inhibitor and angiotensin receptor antagonist valsartan (ARNi). Efficacy of LCZ696 in treating heart failure is based on the PARADIGM-HF trial in which LCZ696 (sacubitril/valsartan) was compared with the angiotensin-converting enzyme inhibitor enalapril in 8,400 patients, in a single phase 3 clinical trial. Results from the studies showed that …
